$DWTX
Dogwood Therapeutics, Inc.

2024 Q1 Form 10-K Financial Statement

#000155837024002239 Filed on March 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $970.4K $839.8K $3.719M
YoY Change -8.42% 2.67% -12.41%
% of Gross Profit
Research & Development $343.7K $298.3K $1.728M
YoY Change -30.94% -76.54% -78.59%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.314M $1.138M $5.447M
YoY Change -15.62% -45.54% -55.77%
Operating Profit -$1.314M -$5.447M
YoY Change -15.62% -55.77%
Interest Expense $22.77K $34.95K $150.9K
YoY Change -43.67% -22.61% 123.62%
% of Operating Profit
Other Income/Expense, Net $22.77K $150.9K
YoY Change -43.68% 123.64%
Pretax Income -$1.291M -$1.103M -$5.296M
YoY Change -14.87% -46.04% -56.76%
Income Tax
% Of Pretax Income
Net Earnings -$1.291M -$1.103M -$5.296M
YoY Change -14.87% -46.04% -56.76%
Net Earnings / Revenue
Basic Earnings Per Share -$0.07 -$0.28
Diluted Earnings Per Share -$0.07 -$0.06 -$0.28
COMMON SHARES
Basic Shares Outstanding 19.26M 19.26M 18.78M
Diluted Shares Outstanding 19.26M 18.78M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.380M $3.317M $3.317M
YoY Change -55.38% -52.82% -52.82%
Cash & Equivalents $2.380M $3.317M
Short-Term Investments
Other Short-Term Assets $845.1K $848.5K $848.5K
YoY Change -28.87% -36.62% -36.62%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.225M $4.165M $4.165M
YoY Change -50.55% -50.23% -50.23%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $3.225M $4.165M $4.165M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $3.225M $4.165M $4.165M
YoY Change -50.55% -50.23% -50.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $196.8K $111.9K $111.9K
YoY Change 45.65% -80.47% -80.47%
Accrued Expenses $373.3K $246.6K $246.6K
YoY Change -9.87% -47.54% -47.53%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $570.1K $358.5K $358.6K
YoY Change 3.79% -65.63% -65.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $570.1K $358.5K $358.6K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $570.1K $358.5K $358.6K
YoY Change 3.79% -65.63% -65.63%
SHAREHOLDERS EQUITY
Retained Earnings -$62.76M -$61.47M
YoY Change 8.79% 9.43%
Common Stock $1.926K $1.926K
YoY Change 5.07% 5.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.655M $3.807M $3.807M
YoY Change
Total Liabilities & Shareholders Equity $3.225M $4.165M $4.165M
YoY Change -50.55% -50.23% -50.23%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$1.291M -$1.103M -$5.296M
YoY Change -14.87% -46.04% -56.76%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$937.4K -$1.469M -$4.870M
YoY Change -44.81% -45.0% -57.53%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.156M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 1.156M
YoY Change -100.0% -74.25%
NET CHANGE
Cash From Operating Activities -937.4K -1.469M -4.870M
Cash From Investing Activities
Cash From Financing Activities 0.000 1.156M
Net Change In Cash -937.4K -1.469M -3.714M
YoY Change -44.81% -46.72% -46.77%
FREE CASH FLOW
Cash From Operating Activities -$937.4K -$1.469M -$4.870M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001818844
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Registrant Name
EntityRegistrantName
Virios Therapeutics, Inc.
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18330390
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-39811
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-4314201
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
44 Milton Avenue
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Alpharetta
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30009
CY2023 dei City Area Code
CityAreaCode
866
CY2023 dei Local Phone Number
LocalPhoneNumber
620-8655
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 Par Value per Share
CY2023 dei Trading Symbol
TradingSymbol
VIRI
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
24371988.18
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19257937
CY2023 dei Auditor Name
AuditorName
FORVIS, LLP
CY2023 dei Auditor Location
AuditorLocation
Atlanta, Georgia
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3316946
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7030992
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
848496
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1338764
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4165442
CY2022Q4 us-gaap Assets Current
AssetsCurrent
8369756
CY2023Q4 us-gaap Assets
Assets
4165442
CY2022Q4 us-gaap Assets
Assets
8369756
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
111913
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
573164
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
246635
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
470098
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
358548
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1043262
CY2023Q4 us-gaap Liabilities
Liabilities
358548
CY2022Q4 us-gaap Liabilities
Liabilities
1043262
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19450888
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19257937
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18330390
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1926
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1833
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
65573300
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
63497868
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61469222
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56173207
CY2023Q4 us-gaap Stockholders Equity Before Treasury Stock
StockholdersEquityBeforeTreasuryStock
4106004
CY2022Q4 us-gaap Stockholders Equity Before Treasury Stock
StockholdersEquityBeforeTreasuryStock
7326494
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
192951
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
299110
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3806894
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7326494
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4165442
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8369756
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1728078
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8069628
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3718841
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4245681
CY2023 us-gaap Operating Expenses
OperatingExpenses
5446919
CY2022 us-gaap Operating Expenses
OperatingExpenses
12315309
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-5446919
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-12315309
CY2023 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
150904
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
67475
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
150904
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
67475
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5296015
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12247834
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-5296015
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-12247834
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.11
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.11
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18776790
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18776790
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11070116
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11070116
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
14501064
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4490605
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
582659
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-12247834
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7326494
CY2023 viri Stock Issued During Period Value Under Sales Agreement
StockIssuedDuringPeriodValueUnderSalesAgreement
1156443
CY2023 viri Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
299129
CY2023 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
299129
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
619972
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-5296015
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3806894
CY2023 us-gaap Profit Loss
ProfitLoss
-5296015
CY2022 us-gaap Profit Loss
ProfitLoss
-12247834
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
619972
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
582659
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-490268
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-429739
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-461251
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
219301
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-223463
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-451662
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4870489
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11467797
CY2022 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
4490605
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1156443
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1156443
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4490605
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3714046
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6977192
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7030992
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14008184
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3316946
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7030992
CY2023 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
299129
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q3 us-gaap Share Price
SharePrice
0.50
CY2022Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5000000
CY2022Q3 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
4490605
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
500000
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.625
CY2022Q3 viri Warrants Exercise Price As Percentage Of Initial Public Offering Price
WarrantsExercisePriceAsPercentageOfInitialPublicOfferingPrice
1.25
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-5296015
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-12247834
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4870489
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11467797
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61469222
CY2023 us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
true
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of these financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include estimated work performed but not yet billed by contract manufacturers, engineers and research organizations, the valuation of equity and stock-based related instruments, and the valuation allowance related to deferred taxes. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from those estimates.</p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Concentrations of Credit Risk</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash is potentially subject to concentrations of credit risk. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.</p>
CY2023Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10142394
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
9023362
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9926772
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8682497
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
702352
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1165634
CY2023Q4 viri Prepaid Clinical Research Costs
PrepaidClinicalResearchCosts
133819
CY2022Q4 viri Prepaid Clinical Research Costs
PrepaidClinicalResearchCosts
154510
CY2023Q4 viri Prepaid Services
PrepaidServices
8766
CY2022Q4 viri Prepaid Services
PrepaidServices
11329
CY2023Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
3559
CY2022Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
7291
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
848496
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1338764
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7132019
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
5692533
CY2023Q4 viri Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
1524035
CY2023Q4 viri Accrued Interest On Preferred Members Interest
AccruedInterestOnPreferredMembersInterest
188085
CY2022Q4 viri Accrued Interest On Preferred Members Interest
AccruedInterestOnPreferredMembersInterest
188085
CY2023Q4 viri Accrued Director Fees Current
AccruedDirectorFeesCurrent
31000
CY2022Q4 viri Accrued Director Fees Current
AccruedDirectorFeesCurrent
31000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
27550
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
11600
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
159704
CY2022Q4 viri Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
78349
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1360
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
246635
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
470098
CY2020Q4 viri Common And Preferred Stock Shares Authorized
CommonAndPreferredStockSharesAuthorized
45000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2023 viri Number Of Votes Per Common Stock
NumberOfVotesPerCommonStock
1
CY2020Q3 viri Employment Agreement Severance Payment Payment Period
EmploymentAgreementSeverancePaymentPaymentPeriod
P1Y
CY2020Q3 viri Employment Agreement Change Of Control Termination Payment Period
EmploymentAgreementChangeOfControlTerminationPaymentPeriod
P45D
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
172500
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.50
CY2021Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2021Q4 viri Warrants Exercisable Percentage
WarrantsExercisablePercentage
1
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
500000
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.625
CY2023Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q1 viri Warrants Exercisable Percentage
WarrantsExercisablePercentage
1
CY2022Q3 viri Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Aggregate Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue
178462
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0369
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9646
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
CY2022Q3 us-gaap Share Price
SharePrice
0.50
CY2023 viri Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
478625
CY2023 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
192951
CY2023 viri Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
285674
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
299110
CY2022Q4 viri Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
1873211
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1441652
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1411624
CY2023Q4 viri Deferred Tax Assets Investment In Partnership
DeferredTaxAssetsInvestmentInPartnership
30639
CY2022Q4 viri Deferred Tax Assets Investment In Partnership
DeferredTaxAssetsInvestmentInPartnership
30771
CY2023Q4 viri Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
14049
CY2022Q4 viri Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
15223
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
172500
CY2021Q4 viri Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
12.50
CY2021 viri Class Of Warrant Or Right Remaining Term
ClassOfWarrantOrRightRemainingTerm
P3Y11M15D
CY2022 viri Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
500000
CY2022 viri Class Of Warrant Or Right Granted Weighted Average Exercise Price
ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice
0.63
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
672500
CY2022Q4 viri Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
3.67
CY2022 viri Class Of Warrant Or Right Remaining Term
ClassOfWarrantOrRightRemainingTerm
P4Y3M7D
CY2023 viri Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
478625
CY2023 viri Class Of Warrant Or Right Exercised Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice
0.63
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
193875
CY2023Q4 viri Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
11.19
CY2023 viri Class Of Warrant Or Right Remaining Term
ClassOfWarrantOrRightRemainingTerm
P2Y1M28D
CY2023 viri Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
193875
CY2023 viri Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
11.19
CY2023 viri Class Of Warrant Or Right Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm
P2Y1M28D
CY2023Q4 viri Aggregate Intrinsic Value Of Warrants Outstanding
AggregateIntrinsicValueOfWarrantsOutstanding
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2023 viri Effective Income Tax Rate Reconciliation Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
-0.0201
CY2022 viri Effective Income Tax Rate Reconciliation Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
-0.0057
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0430
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0483
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0020
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0006
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2349
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2532
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
215622
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
340865
CY2023Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
215622
CY2022Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
340865
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
215622
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
340865
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023 viri Capitalized Research And Development Expense
CapitalizedResearchAndDevelopmentExpense
1728078
CY2022 viri Capitalized Research And Development Expense
CapitalizedResearchAndDevelopmentExpense
8099702
CY2022Q4 viri Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
1873211
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1244274
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3100898
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
686

Files In Submission

Name View Source Status
0001558370-24-002239-index-headers.html Edgar Link pending
0001558370-24-002239-index.html Edgar Link pending
0001558370-24-002239.txt Edgar Link pending
0001558370-24-002239-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20231231.xsd Edgar Link pending
tmb-20231231x10k.htm Edgar Link pending
tmb-20231231x10k001.jpg Edgar Link pending
tmb-20231231x10k002.jpg Edgar Link pending
tmb-20231231x10k003.jpg Edgar Link pending
tmb-20231231x10k004.jpg Edgar Link pending
tmb-20231231xex23d1.htm Edgar Link pending
tmb-20231231xex31d1.htm Edgar Link pending
tmb-20231231xex31d2.htm Edgar Link pending
tmb-20231231xex32.htm Edgar Link pending
tmb-20231231xex97.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
tmb-20231231_cal.xml Edgar Link unprocessable
tmb-20231231_def.xml Edgar Link unprocessable
tmb-20231231_lab.xml Edgar Link unprocessable
tmb-20231231_pre.xml Edgar Link unprocessable
tmb-20231231x10k_htm.xml Edgar Link completed